Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Immuneering Corp IMRX

Healthcare Biotechnology
Immuneering Corporation is a clinical-stage oncology company. The Company is engaged in the development of medicines for cancer patients with universal-RAS therapy. The Company’s lead product candidate, IMM-1-104, in under Phase I/IIa clinical trial in patients with advanced solid tumors harboring RAS mutations. IMM-1-104 is being developed as a once-daily oral monotherapy that aims to achieve... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:IMRX)

Immuneering Reports Third Quarter 2024 Financial Results and Provides Business Updates

GlobeNewswire 8 days ago

Immuneering Granted Orphan Drug Designation for IMM-1-104 by FDA in the Treatment of Pancreatic Cancer

GlobeNewswire October 15, 2024

Immuneering Announces Positive Initial Phase 2a Data Including Complete and Partial Responses with IMM-1-104 in Combination with Chemotherapy in First-Line Pancreatic Cancer Patients

GlobeNewswire September 12, 2024

Immuneering to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference

GlobeNewswire August 29, 2024

Immuneering Reports Second Quarter 2024 Financial Results and Provides Business Updates

GlobeNewswire August 6, 2024

Immuneering Granted FDA Fast Track Designation for IMM-1-104 in First-line Pancreatic Cancer

GlobeNewswire July 31, 2024

Immuneering to Present at the Jefferies Global Healthcare Conference

GlobeNewswire May 29, 2024

Immuneering Reports First Quarter 2024 Financial Results and Provides Business Updates

GlobeNewswire May 7, 2024

Immuneering Recognizes Melanoma Awareness Month

GlobeNewswire May 6, 2024
View More News ››

Opinion & Analysis (NDAQ:IMRX)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:IMRX)

BUY BUY BUY BUY BUY

To reach 4$ in pre market
Nibinator - July 31, 2024
View more Bullboard ››

Good Natured Products Inc

Good Natured Products Inc

good natured Products Inc. offers an assortment of plant-based products made all, or in part, from the maximum possible ...
View More »